home / stock / afmd / afmd quote
Last: | $5.37 |
---|---|
Change Percent: | 0.75% |
Open: | $5.33 |
Close: | $5.33 |
High: | $5.4 |
Low: | $5.11 |
Volume: | 23,681 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.37 | $5.33 | $5.33 | $5.4 | $5.11 | 23,681 | 03-28-2024 |
$5.33 | $5.41 | $5.33 | $5.65 | $5.3 | 99,631 | 03-27-2024 |
$5.32 | $5.21 | $5.32 | $5.57 | $5.1985 | 57,641 | 03-26-2024 |
$5.19 | $5.05 | $5.19 | $5.19 | $4.87 | 98,131 | 03-25-2024 |
$4.99 | $5.05 | $4.99 | $5.15 | $4.77 | 68,743 | 03-22-2024 |
$5.04 | $5.29 | $5.04 | $5.485 | $5.01 | 74,153 | 03-21-2024 |
$5.29 | $5.06 | $5.29 | $5.33 | $4.86 | 105,022 | 03-20-2024 |
$5.1 | $4.55 | $5.1 | $5.14 | $4.55 | 107,687 | 03-19-2024 |
$4.54 | $4.58 | $4.54 | $5.04 | $4.51 | 100,486 | 03-18-2024 |
$4.57 | $4.49 | $4.57 | $4.6999 | $4.326 | 75,358 | 03-15-2024 |
$4.4 | $4.8 | $4.4 | $4.86 | $4.245 | 244,383 | 03-14-2024 |
$4.79 | $5.3 | $4.79 | $5.37 | $4.79 | 182,961 | 03-13-2024 |
$5.29 | $5.38 | $5.29 | $5.95 | $5.0501 | 196,266 | 03-12-2024 |
$5.38 | $5.88 | $5.38 | $6.7351 | $5.28 | 201,655 | 03-11-2024 |
$6.079 | $5.801 | $6.079 | $6.1 | $5.8 | 606,782 | 03-08-2024 |
$0.5822 | $0.5799 | $0.5822 | $0.629399 | $0.5601 | 723,250 | 03-07-2024 |
$0.57 | $0.587 | $0.57 | $0.612 | $0.5 | 2,902,157 | 03-06-2024 |
$0.669 | $0.7 | $0.669 | $0.7198 | $0.62 | 443,369 | 03-05-2024 |
$0.69 | $0.7 | $0.69 | $0.72 | $0.68 | 1,472,014 | 03-04-2024 |
$0.67 | $0.62 | $0.67 | $0.696 | $0.6 | 1,348,408 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full ye...